Sichuan Biokin Pharmaceutical Co., Ltd.: Breast Neoplasms trials
The registry lists 15 Breast Neoplasms studies with Sichuan Biokin Pharmaceutical Co., Ltd. as lead sponsor. 11 are open to participants now and 0 have results posted.
Phase 1 12Phase 2 2Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsRecruitingNCT07753226Phase 1
- A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast CancerRecruitingNCT07678957Phase 2
- A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)RecruitingNCT07648914Phase 3
- A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT07274852Phase 1
- A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsRecruitingNCT06609187Phase 1
- A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid TumorsRecruitingNCT06503783Phase 1
- A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsRecruitingNCT06493864Phase 1
- Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid TumorsRecruitingNCT06293898Phase 1
- A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast CancerRecruitingNCT06042894Phase 2
- A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsRecruitingNCT05470348Phase 1
- A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid TumorsRecruitingNCT05461768Phase 1
- Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid TumorsTerminatedNCT06714617Phase 1
- A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid TumorsActive, not recruitingNCT05339685Phase 1
- A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast CancerActive, not recruitingNCT05160545Phase 1
- A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid TumorsWithdrawnNCT05039931Phase 1